ArticleFrontiers in psychiatry2025
Depressive and anxiety disorders in Polish children across the COVID-19 pandemic: a nationwide registry-based time-trend analysis.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The COVID-19 pandemic profoundly disrupted the mental health landscape for children and adolescents in Poland. This study presents a comprehensive analysis of psychotropic medication use, sick-leave days, and psychiatric treatment rates among Polish youth from 2018 to 2024, encompassing pre-pandemic, pandemic, and post-pandemic periods. Methods: In the study we used national-level datasets. Data on Rx (recipe) purchases were obtained from IQVIA Pharmascope database for medication consumption by patients in community pharmacies. We have further examined the combined annual number of sick-leave days for 2020-2024. This data was obtained directly from the Social Insurance Institution of Poland. Lastly, we considered the dataset consisting of annual counts of children, who received at least one intervention in psychiatric care during the examined period. Results: We observed a sharp increase in antidepressant, anxiolytic, and antipsychotic prescriptions during the pandemic peak in 2021, followed by divergent post-pandemic trends-short-acting anxiolytics declined, while antidepressants and antipsychotics remained elevated. Only sertraline shows no clear peak, but rather a steady increase over the analyzed period. Concurrently, sick-leave days due to mental health diagnoses and the number of treated patients rose significantly, indicating sustained psychological distress beyond the acute crisis. Statistical analysis revealed strong upward trends for specific medications, such as escitalopram and quetiapine, and highlighted the pandemic's distorting effect on prescribing patterns. Discussion: These findings underscore the long-term impact of COVID-19 on youth mental health and emphasize the need for enhanced early intervention, expanded access to psychiatric care, and robust public health strategies tailored to children and adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.